Next 10 |
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...
2024-05-23 06:45:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows o...
2024-05-08 16:45:10 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q1 2024 Earnings Call May 08, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q1 2024 Earnings C...
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference PR Newswire NEWTON, Mass. , May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies...
2024-05-08 15:38:52 ET Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Conference Call May 8, 2024 08:00 ET Company Participants Elhan Webb - Senior Vice President of Investor Relations Richard Paulson - President & Chief Executive Officer Reshma Rangwal...
2024-05-08 11:06:28 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts Karyopharm Therapeutics Q1 2024 Earnings Preview Karyopharm Therapeutics GAAP EPS of -$0.36 misses by $0.07, revenue of $33.7M beats by $0.08M ...
2024-05-08 07:33:56 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript Karyopharm Therapeutics Inc. 2023 Q4 - Results - Earnings Call Presentation ...
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 PR Newswire – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Millio...
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and ...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...